Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: An empirical cross-sectional study

Revista Brasileira de Psiquiatria

Volumn 36, Issue 4, 2014, Pages 293-297

  Aydemir, Ömer ^a   Çubukçuoğlu, Zeynep ^a   Erdin, Soner ^a   Taş, Cumhur ^a   Onur, Ece ^a   Berk, Michael ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Biomarkers; Bipolar disorder; Neurocognition; Oxidative stress; Psychosocial functioning

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; NEUROTROPHIN 4; NITRIC OXIDE; PSYCHOTROPIC AGENT; SUPEROXIDE DISMUTASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR DISORDER FUNCTIONING QUESTIONNAIRE; COGNITION; COGNITIVE DEFECT; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOUSEHOLD; HUMAN; LEISURE; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; OXIDATIVE STRESS; PSYCHOLOGIC TEST; QUESTIONNAIRE; REMISSION; REST; REY AUDITORY VERBAL LEARNING TEST; SENSE OF STIGMATIZATION; SERIAL DIGIT LEARNING TEST; SOCIAL BEHAVIOR; SOCIAL PSYCHOLOGY; STROOP TEST; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; WISCONSIN CARD SORTING TEST; YOUNG MANIA RATING SCALE; CASE CONTROL STUDY; DAILY LIFE ACTIVITY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIAL ADAPTATION; TIME;

ACTIVITIES OF DAILY LIVING; ADULT; BIOLOGICAL MARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; PSYCHIATRIC STATUS RATING SCALES; SOCIAL ADJUSTMENT; TIME FACTORS;

EID: 84912551627     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2013-1299     Document Type: Article

References (23)

1. Berk M, Conus P, Kapczinski F, Andreazza AC, Yücel M, Wood SJ, et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust. 2010;193:S36-40
2. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804-17
3. Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav. 2012;106:46-50
4. Kapczinski F, Dias VV, Kauer-Sant’Anna M, Brietzke E, Vázquez GH, Vieta E, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1366-71
5. Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry. 2013;28:21-9
6. Kapczinski F, Dias VV, Kauer-Sant’Anna M, Frey BN, Grassi-Oliveira R, Colom F, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother. 2009;9:957-66
7. Aydemir O, Deveci A, Icelli I. Reliability and validity of the Turkish version of the structured interview guide forHamiltonDepression Rating Scale seasonal affective disorder. Psychiatr Turkey. 2006;8:18-21
8. Karadag F, Oral ET, Yalcin AF, Erten E. [Reliability and validity of Turkish translation of Young Mania Rating Scale]. Turk Psikiyatri Derg. 2002;13:107-14
9. Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord. 2010;12:351-63
10. Aydemir O, Eren I, Savas¸ H, Kalkan Oguzhanoglu N, Kocal N, Devrimci Ozguven H, et al. [Development of a questionnaire to assess inter-episode functioning in bipolar disorder: Bipolar Disorder Functioning Questionnaire]. Turk Psikiyatri Derg. 2007;18:344-52
11. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sögü t S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/ antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:995-1005
12. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002; 20:171-5
13. Kaya E, Aydemir O, Selcuki D. Residual symptoms in bipolar disorder: the effect of the last episode after remission. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1387-92
14. Mann-Wrobel MC, Carreno JT, Dickinson D. Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables. Bipolar Disord. 2011;13:334-42
15. Rosa AR, Reinares M, Franco C, Comes M, Torrent C, Sánchez- Moreno J, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord. 2009;11:401-9
16. Ozer S, Ulusahin A, Batur S, Kabakci E, Saka MC. Outcome measures of interepisode bipolar patients in a Turkish sample. Soc Psychiatry Psychiatr Epidemiol. 2002;37:31-7
17. Goldberg JF. Adverse cognitive effects of psychotropic medications. In: Goldberg JF, Burdick KE, editors. Cognitive dysfunction in bipolar disorder: a guide for clinicians. Arlington: American Psychiatric Publishing; 2008. p. 137-58
18. Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom. 2009;78:285-97
19. Depp CA, Davis CE, Mittal D, Patterson TL, Jeste DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry. 2006;67:215-21
20. Bora E, Vahip S, Akdeniz F, Gonul AS, Eryavuz A, Ogut M, et al. The effect of previous psychotic mood episodes on cognitive impairment in euthymic bipolar patients. Bipolar Disord. 2007;9:468-77
21. Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9:671-8
22. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord. 2007;100:279-81
23. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41:523-9.